Compare Twist Bioscience Corp (TWST) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Uranium Energy Corp — how do they compare? Twist Bioscience Corp trades at $160.26 (market cap $10.08B), while Uranium Energy Corp trades at $9.21 (market cap $4.53B). The key difference: Twist Bioscience Corp is far larger — about 2.2× Uranium Energy Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Uranium Energy Corp for 37 Days on average.
| TWST | UEC | |
|---|---|---|
Market Cap | $10.08B | $4.53B |
Volume | 4,229,037 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $205.00 | $20.14 |
52-Week Low | $25.45 | $9.04 |
Typical Hold Time | 27 Days | 37 Days |
Enterprise Value | $10.01B | $4.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
UEC trades at $9.24, down 2.43% on the day, amid a bearish technical signal with moving averages indicating selling pressure. The company reported a net loss of -$87.66M in 2025, with revenue of $66.84M and a deeply negative net income margin of -368.62%. Recent news highlights operational expansion to two mines, but earnings misses in Q1 and Q2 2026 raise concerns about sustainability despite a Q4 beat.
Wall Street analysts remain bullish with an 87.5% buy rating and a $16.06 consensus price target, citing U.S. uranium demand growth. However, high cash burn, reliance on financing, and unproven production sustainability pose significant risks. The stock offers speculative upside if operational execution improves, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
